polymyxin b-2

Polymyxin B2 is an antibiotic primarily utilized for resistant Gram-negative infections. It is derived from the bacterium Bacillus polymyxa.

Polymyxin B2, a significant component of polymyxin B, is an antibiotic cationic lipopeptide initially derived from B. polymyxa. This compound effectively inhibits P. aeruginosa, A. baumannii, K. pneumoniae, and E. cloacae strains, exhibiting minimum inhibitory concentrations (MICs) of 1-2, 0.5-1, 0.25-0.5, and 0.25-1 µg/ml, respectively. Notably, in a mouse model of P. aeruginosa bloodstream infection, administration of polymyxin B2 at a dosage of 4 mg/kg has been shown to decrease the number of colony-forming units (CFUs) in the blood.

Polymyxin B2-[13C6,15N] Tfa Salt (Standard) is a reference standard of Polymyxin B2-[13C6,15N] Tfa Salt intended for quantitative analysis, quality control, and related biochemical research applications.

IKD-8344 is a macrocyclic dilactone originally isolated from an actinomycete species with diverse biological activities, including anticancer, antimicrobial, and anthelmintic properties [1,2,3]. It is cytotoxic to L5178Y murine leukemia cells (IC50 = 0.54 ng/ml) [1], inhibits growth of the mycelial form of C. albicans (MIC = 6.25 μg/ml), and potentiates the activity of polymyxin B against the multidrug-resistant pathogenic bacterium B. cenocepacia [2,3]. Additionally, it is active against T. spiralis in vitro and in vivo [1].

Polymyxin E1, a peptide antibiotic and key component of the cationic lipopeptide antibiotic colistin, was initially extracted from B. polymyxa. It demonstrates effectiveness against P. aeruginosa and E. coli, with minimum inhibitory concentrations (MICs) of 2 µg/ml and 0.8 µg/ml, respectively.